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Abstract The therapeutic activity of 131I administered to
patients with Graves’ disease can be calculated by means of
Marinelli’s formula. The thyroidal iodine uptake (131IUmax)
needed for the calculation is usually determined with the
use of 131I. The purpose of the paper was to estimate
131IUmax on the basis of technetium uptake in the thyroid at
20 min (99mTcU20min). Eighty patients suffering from
Graves’ disease were qualiﬁed for radioiodine therapy with
measurement of fT4, fT3, thyroid-stimulating hormone and
its receptor (TRAb). Prior to the treatment, all the patients
were euthyroid. 131IUmax for each patient was determined
according to the levels of 131I after 24 h (131IU24h), while
effective half-life (Teff) according to the measurements of
131IU24h and
131I uptake after 48 h (131IU48h). Additionally,
on the day before measuring 131IU24h,
99mTcU20min was
calculated for each patient. It was demonstrated that there
existed a correlation, with statistical signiﬁcance at




131IU24h. The interdependence between
131IU24h and
99mTcU20min at the level of signiﬁcance p< 0.05 is descri-
bed by the following algorithms: 131IU24h= 17.72 × ln
(99mTcU20min) + 30.485, if TRAb < 10 IU/ml, and
131IU24h
= 18.03 × ln (99mTcU20min) + 38.726, if TRAb> 10 IU/ml.
It is possible to predict thyroid iodine uptake 131IU24h in
Graves’ disease on the basis of measuring the uptake of
99mTcU20min. This shortens the time necessary for diagnosis
and enables the calculation of 131I activity using Marinelli’s
formula.
Keywords Marinelli’s formula ● Thyroid iodine uptake ●
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Introduction
Radiotherapy is, apart from pharmacotherapy and surgical
intervention, one of the major methods of treatment for
Graves’ disease (GD). Effective radioiodine therapy for GD
consists in calculating an appropriate activity of the radio-
isotope in order to achieve the highest possible therapeutic
efﬁcacy, with the lowest possible radiation of the thyroid,
and thus of the patient. The clinics that offer radioiodine
therapy in Europe and around the world use various
methods of selecting correct therapeutic activities of 131I.
Our department applies the Marinelli formula, which is
recommended by the European Association of Nuclear
Medicine (EANM) [1]. Radioiodine 131I is usually used to
determine the thyroidal iodine uptake required by the for-
mula. Some also use the iodine isotope 123I, although much
less frequently because of the high costs of its production in
a cyclotron [2, 3]. The disadvantages of using 131I for
therapeutic purposes include: beta radiation during radio-
active decay, relatively high gamma radiation energy (364
keV) and the long time (usually 24 h) that is required for
assessing the maximum iodine uptake in the thyroid.
Technetium 99mTc is another isotope which, like 131I, is
absorbed by thyrocytes, thanks to sodium/iodide symporter
(NIS) proteins. Contrary to 131I, it is a pure emitter of
gamma radiation, with a much shorter half-life (T1/2) of
6.04 h (8 days in the case of 131I). Moreover, the gamma
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radiation of technetium carries far less energy than that of
iodine (140 keV). Also the time needed for the assessment
of its maximum uptake by the thyroid is much shorter than
in the case of 131I and equals only 20 min. This allows to
diminish the time of thyroid diagnostic. As far as their
metabolism in thyroid cells is concerned, a major difference
between 99mTc and 131I is that the former does not partici-
pate in the synthesis of hormones. Nevertheless, the thyr-
oidal uptake of both 9mTc and 131I in GD depends primarily
on the level of thyroid-stimulating hormone (TSH) receptor
antibodies (TRAbs), which stimulate the NIS protein to
active transport of isotopes into thyrocytes, as well as by
intercellular metabolism [4, 5]. The question arises, there-
fore, whether the assessment of thyroid iodine uptake nee-
ded for Marinelli’s formula could be performed with the
help of 99mTc. Thus the aims of this study were as follows:
(1) An attempt to create an algorithm to assess thyroidal
iodine uptake in GD patients qualiﬁed for radioactive
iodine therapy on the basis of 99mTc scintigraphy of
the thyroid.
(2) Transformation of Marinelli’s formula used for
calculating therapeutic activities of 131I by substituting
thyroid iodine uptake with thyroid 99mTc uptake.
Materials and methods
The study sample comprised 80 GD patients: 61 women
and 19 men. All the subjects had been referred to the
Department of Nuclear Medicine with a view to treating
hyperthyroidism, following unsuccessful attempts at phar-
macotherapy with thyrostatic drugs (the treatment periods
being no shorter than 1.5 years). Prior to the administration
of a therapeutic dose of 131I, each patient had undergone
routine eligibility screening, involving an initial measure-
ment of the thyrotropic hormone, TSH (reference range 0.3–
4.0 µIU/ml), free thyroxine, fT4 (reference range 0.71–1.85
ng/dl) and free triiodothyronine, fT3 (reference range
1.45–3.48 pg/mL), using the immunoenzymatic method,
Microparticle Enzyme Immunoassay (Abbott Park, USA),
and TSH-TRAb (normal< 2 IU/l) using the radio-
immunological method (TRAK Human BRAHMS,
Germany). Subsequently it was decided that further diag-
nostics could only involve those subjects who were euthyr-
oid. Hyperthyroid patients continued to be treated with
thyrostatics until euthyroid, up to 2 days before the study.
Next, the 24- and 48-h thyroidal iodine uptake tests were
carried out after per os (fasting) administration of a capsule
containing 131I with the activity of 4 MBq. Additionally, 1
day before the IU24h, scintigrams of the thyroid glands were
performed, following an intravenous administration of 80
MBq 99mTc. The readouts of thyroid-absorbed radiation
began at 20 min of the administration of the radio marker.
Both the iodine uptake tests and the technetium scintigraphy
estimating the marker’s uptake in the gland were performed
with a gamma-camera (NuclineTM Th, Mediso, Hungary),
in accordance with the standard procedures. The volume of
the thyroid (m) was estimated by means of a ultra-
sonography (USG). USG device was equipped with a 12 L
linear transducer (LOGIQ S8, GE Healthcare, USA).
The required therapeutic activity of 131I (A) was calcu-
lated with Marinelli’s formula [6]:
A ¼ 25  m  D
IU24h  Teff
where
A—131I therapeutic activity (MBq)
25—unit conversion coefﬁcient
m—mass of thyroid gland calculated with USG (g)
D—absorbed dose of 131I (Gy), with D= 150 Gy, as




131I half-life in thyroid gland (days) cal-
culated with gamma-camera based on 131IU24h and
131IU48h
The study was approved by the Ethics Committee for
Medical Research, Medical University, and is compliant
with the good clinical practice guidelines. Informed consent
was given by all patients participating in the study.
Statistical analysis
The statistical analysis of the results of the study was
conducted using the software package Statistica 10 (Stat
Soft, Tulsa, USA).
A multivariate analysis of variance was used to investi-
gate the inﬂuence of fT4, fT3, TSH, m and TRAb on IU24h,
Teff and
99mTcU20min. The signiﬁcance level was p< 0.05.
The non-linear regression function was used to establish
the correlation of the IU24h,
99mTcU20min and TRAb para-
meters, with the level of signiﬁcance at p< 0.05.
Results
It can be noticed among the parameters measured in GD
patients in the course of the eligibility study, the effective
131I half-life in the thyroid gland (Teff) has a very low
standard deviation (±0.04) and that its mean value equals
5.5 days, while the serum level of thyroid hormones in all
the patients before treatment remains within the normal
limits, thanks to an effective therapy with thyrostatic med-
ications (Table 1).
Comparison of the parameters measured in the patients
during the eligibility screening period demonstrates that
752 Endocrine (2016) 54:751–756
there exists a statistically signiﬁcant (p< 0.05) correlation




The statistical analysis revealed that the highest correla-
tion between 99mTc and 131I occurs when the TRAb titre is
either <10 IU/ml or >10 IU/ml.
Using this information, further analysis involved the
non-linear regression model in order to generate a mathe-
matical formula that would describe the relationship
between 131IU24h and
99mTcU20min for the two ranges of
TRAb titres, assuming the signiﬁcance at p< 0.05. It stems
from the calculations (Figs. 1 and 2) that the regression
model that predicts the dependence of IU24h on
99mTcU20min, if TRAb < 10 IU/ml, looks as follows:
131IU24h ¼ 17:72 ´ lnð99mTcU20minÞ þ 30:485
whereas if TRAb > 10 IU/ml:
131IU24h ¼ 18:03 ´ lnð99mTcU20minÞ þ 38:726
By substituting 131IU24h in the Marinelli formula with the
above correlations, and Teff with the number 5.5 (the value
of Teff in all the patients equalled approximately 5.5; see
Table 1), we will obtain transformed formulas that can be
used to calculate the therapeutic activity of 131I on the basis
of thyroid 99mTcU20min uptake.
If TRAb < 10 IU/ml, the transformed Marinelli’s formula
takes this form:
A MBqð Þ ¼ 25 ´mðgÞ ´DðGÞ
17:72 ´ ½lnð99mTcU20minÞ þ 30:485 ´ 5:5
whereas if TRAb > 10 IU/ml, it looks as follows:
AðMBqÞ ¼ 25 ´mðgÞ ´DðGÞ
18:03 ´ ½lnð99mTcU20minÞ þ 38:726 ´ 5:5
Discussion
The therapeutic effect of the ionising radiation of 131I applied
in the course of hyperthyroidism treatment depends above all
on the dose of radiation absorbed by the thyroid gland. This
statement is one of the key points of the standards regarding
radioiodine treatment for hyperthyroidism issued by the
EANM. The EANM guidelines mention the ranges of
absorbed doses of ionising radiation according to the type of
hyperthyroidism. In patients with autonomous nodules, the
recommended dose is 300–400 Gy. In patients with GD, the
dose with the aim of restoring a euthyroid status is
approximately 150 Gy, whereas the dose to achieve complete
ablation is in the range 200–300 Gy. For calculating the
therapeutic activity of radioiodine, the EANM guidelines
recommend the Marinelli formula. Apart from the afore-
mentioned absorbed dose, the formula requires the evaluation
of maximum thyroidal iodine uptake and of the effective
half-life of radioiodine in the thyroid [1]. In an accurately
prepared GD patient, the effective half-life has—according to
our calculations—a steady value of 5.5 days on average
[7–10]. This is why we are convinced that Marinelli’s for-
mula can be simpliﬁed by substituting Teff with 5.5 days.
In their attempts to streamline the calculation of the
therapeutic activity of radioactive iodine using Marinelli’s
formula, some authors resort to a variety of methods to
determine the value of maximum thyroid iodine uptake. As a
rule, the maximum uptake occurs after 24 h of the
Table 1 Parameters measured
during eligibility screening










m (g) 99mTcU20min (%) IU24h (%) Teff (days)
Mean 1.34 2.54 1.21 10.9 31.6 2.3 45 5.5
Standard
deviation
±0.19 ±0.36 ±0.4 ±14.8 ±18.6 ±3.4 ±15.8 ±0.04
Maximum 4.67 3.31 1.41 39.7 64.3 8.1 68 5.9
Minimum 0.54 1.54 1.01 1.7 19.4 1.1 32 5.17
fT4 free thyroxine, fT3 free triiodothyronine, m mass of thyroid,
99mTcU20min 20-min
99mTc uptake, IU24h
24-h 131I uptake, Teff effective
131I half-life in thyroid gland, TRAb antibodies against TSH receptor, TSH
thyroid-stimulating hormone
Fig. 1 Scatter graph for variables 99mTcU20min and
131IU24h, with
TRAbo 10 IU/ml, and regression equation illustrating their
relationship
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administration of radioactive iodine (131I) [10–12]. Morris
and Hayes et al. propose algorithms for predicting 131I uptake
through measuring it after 4 or 6 h, which considerably
shortens the time of the procedure. In Morris’ study, the
difference between the actual 24 h measurement and the
estimated value after 4 h amounted to +10%, and +5.9%
after 6 h. Hayes et al., meanwhile, proved that the correlation
coefﬁcient between the actual measurements and the 4- and
6-h estimates was high, reaching r= 0.94 [13, 14].
Still another approach to the problem can be found in the
research results published by authors such as Shapiro or
Yaqub. In both studies the maximum thyroid uptake in GD
patients was calculated—as it usually is—after 24 h, but it
was done by means of 123I instead of 131I. 123I possesses
better physical parameters for isotope diagnostics (123I, in
contrast to 131I, is a pure emitter of gamma radiation,
characterised by a lower energy level and shorter half-life)
[15, 16]. Osaki et al. combined the above two approaches to
calculating IUmax based on Marinelli’s formula by assuming
that it represented by the value of 24 h thyroidal iodine
uptake and can be predicted using the 123I uptake after 3 h.
They claim in their publication that the algorithm they
propose for determining the correlation between the 3- and
the 24-h thyroidal iodine uptake is statistically signiﬁcant
(p< 0.001) and can be used in clinical practice [8]. It has to
be noted, however, that as for practical application, this
method has the distinct disadvantage of being expensive,
especially in Poland. The costs of producing the cyclotron-
based iodine isotope 123I far outweighs those of acquiring
the widely used reactor-produced isotope of iodine, 131I.
Smith et al. present yet another strategy for assessing
IUmax in the thyroid, although their research was conducted
on patients with non-toxic goitre, not with GD as in the case
of the previously mentioned authors. Departing from an
analysis of the measurements of thyroid 99mTc and 131I
uptake in each of their 44 patients, Smith et al. created an
algorithm estimating the 24-h thyroid radioactive iodine
uptake based on the level of 99mTc uptake at 5 min of
administering the radiomarker. They also emphasise that
assessing iodine uptake on the basis of technetium
Fig. 2 Scatter graph for variables 99mTcU20min and
131IU24h, with
TRAb4 10 IU/ml, and regression equation illustrating their
relationship
Table 2 Coefﬁcients of correlation between parameters
TSH (µIU/ml) fT4 (ng/dl) fT3 (pg/ml) m (g) TRAb (IU/l)
99mTcU20min (%)
131IU24h (%) Teff (days)
TSH (µIU/ml)
fT4 (ng/dl) r= 0.56
(p= 0.072)
fT3 (pg/ml) r= 0.43 r = 0.59
(p= 0.091) (p= 0.301)
m (g) r= 0.24 r = 0.31 r= 0.28
(p= 0.086) (p= 0.201) (p= 0.501)
TRAb (IU/l) r= 0.2 r = 0.43 r= 0.35 r = 0.23
(p= 0.123) (p= 0.078) (p= 0.101) (p= 0.134)
99mTcU20min (%) r= 0.34 r = 0.56 r= 0.66 r = 0.37 r= 0.70
a
(p= 0.061) (p= 0.058) (p= 0.069) (p= 0.068) (p= 0.013)
131IU24h (%) r= 0.57 r = 0.54 r= 0.51 r = 0.32 r= 0.73
b r= 0.89c
(p= 0.056) (p= 0.059) (p= 0.059) (p= 0.081) (p= 0.021) (p= 0.031)
Teff (days) r= 0.47 r = 0.61 r= 0.46 r = 0.198 r= 0.28 r= 0.31 r = 0.5
(p= 0.057) (p= 0.061) (p= 0.072) (p= 0.203) (p= 0.078) (p= 0.099) (p= 0.105)
Abbreviations: see Table 1
a,b,c Correlation coefﬁcients occurring with statistical signiﬁcance of p< 0.05
The other correlation coefﬁcients in the table do not meet the p< 0.05 condition
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scintigraphy allows for the greatest reduction of the patients’
exposure to ionising radiation. The thyroid absorbed dose of
radiation emitted by technetium is 10 times as low as it is
when 123I is used, and 10,000 lower than in the case of
treatment with 131I. Also the effective dose of ionising
radiation received by the entire organism is markedly lower
when technetium is used for testing instead of 123I or 131I
iodine [17]. The exposition from the diagnostic activity of
radioiodine is unimportant considering the dose received
from the following radioiodine therapy. Our study uses
similar assumption as regards the prediction of thyroidal
iodine uptake on the basis of technetium uptake, the only
difference being that our sample consisted of patients with
GD. The choice of study sample was determined by the fact
that in GD the thyroid tissue is usually homogeneous and
there are no problems associated with the occurrence of
nodules that take up 99mTc and 131I in different ways, as it is
sometimes the case in a nodular goitre. These discrepancies
result from the lack of 99mTc organiﬁcation by thyrocytes,
which occurs when 131I is used [18]. Had we additionally
taken into consideration the measurements of uptake values
for the nodular goitre, the study sample would have become
overly heterogeneous, making the calculations imprecise.
According to our investigations, the algorithm that
depicts the correlation between the uptakes of 131I and
99mTc is determined by the level of TRAb antibodies. The
level of TRAb that signiﬁcantly changes the algorithm
equals 10 IU/ml. In clinical practice, this means that when
thyroidal iodine uptake is estimated in GD patients on the
basis of 99mTc uptake, the level of TRAb antibodies should
be taken into account so as to apply the correct algorithm.
In conclusion, predicting the thyroidal uptake of 131IU24h
in GD on the basis of measuring 99mTcU20min uptake is
possible, thanks to the equation created in the course of our
research. The application of this algorithm considerably
shortens the time necessary for pre-therapy diagnostic pro-
cedures and makes it possible to calculate the therapeutic
activity of radioactive iodine with the use of Marinelli’s
formula, as recommended by the EANM.
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